Qiagen N.V. is a global biotechnology company that specializes in providing sample and assay technologies for molecular diagnostics, pharmaceutical development, and academic research. The company develops innovative solutions that enable the extraction, purification, and analysis of nucleic acids, such as DNA and RNA, from various biological samples. Qiagen's products are designed to enhance the speed and accuracy of molecular testing, supporting the detection of diseases, genetic analysis, and the development of personalized medicine. With a strong commitment to advancing scientific research and improving healthcare outcomes, Qiagen collaborates with a range of industries and institutions to deliver reliable and efficient tools for life sciences research and clinical applications. Read More
Wall Street breathed a collective sigh of relief this week as fresh economic data suggested that the "Great Data Gap" of 2025 might finally be closing with a soft landing in sight. Following a record-breaking 43-day federal government shutdown that ended in mid-November, the first comprehensive look at inflation and
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced details for completion of plans to return approximately $500 million to shareholders through a synthetic share repurchase that combines a direct capital repayment to QIAGEN shareholders with a reverse stock split.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the debut of QIAsymphony Connect, the next generation of QIAGEN’s widely adopted automated nucleic acid purification platform, at the 2025 AMP (Association for Molecular Pathology) annual meeting from November 11-15 in Boston.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for the third quarter of 2025 and reaffirmed its outlook for solid profitable growth while raising its profitability targets.
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a definitive agreement to fully acquire Parse Biosciences, a leading provider of scalable, instrument-free solutions for single-cell research.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the EZ2 DNA Investigator Sep&Prep Kit, a fully automated solution for processing sexual assault samples, at the upcoming International Symposium on Human Identification 2025 (ISHI) from November 3-6 in Palm Beach, Florida.
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the 4,000th placement of its QIAcube Connect instrument, a significant milestone in driving automation adoption for sample processing across life science and diagnostic labs.
QIAGEN NV exemplifies the Caviar Cruise investing method with strong sales growth, a 46% ROIC, and robust cash flow, signaling a high-quality business.
San Diego, CA – October 1, 2025 – Illumina, Inc. (NASDAQ: ILMN) saw its shares surge by 6.6% today following the announcement and immediate launch of its new business unit, BioInsight. This strategic move marks a significant pivot for the genomic sequencing giant, as it ventures deeper into the burgeoning fields
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has achieved CE-IVDR certification for its full portfolio of QIAstat-Dx syndromic testing systems and panels, including an expanded Meningitis/Encephalitis (ME) Panel that sets a new benchmark in the diagnosis of central nervous system (CNS) infections.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of QIAstat‑Dx Rise – a version of the QIAstat-Dx automated syndromic testing system that offers unparalled throughput with the easiest workflow available to customers worldwide.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced solid results for Q2 2025 that exceeded the outlook, and increased the full-year 2025 outlook for net sales growth while reaffirming the adjusted diluted earnings per share (EPS) target that was raised earlier in the year.
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its new QIAseq xHYB Long Read Panels, a suite of target enrichment solutions designed to unlock long-read sequencing of genomically complex regions.
QIAGEN N.V. (NYSE:QGEN) shows strong technicals and a high-quality breakout setup, making it a candidate for momentum traders. The stock trades near 52-week highs with clear support and resistance levels.
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its Supervisory Board has elected Stephen H. Rusckowski as Chairman following the Annual General Meeting of Shareholders (AGM) on June 26, 2025.
QIAGEN N.V. (NYSE:QGEN) is a quality stock with strong revenue growth, high ROIC, and solid cash flow conversion, making it a candidate for long-term investors.
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and GENCURIX, Inc. (KOSDAQ: 229000) today announced a new partnership to develop oncology assays for use on the QIAcuityDx platform, a high-performance digital PCR system designed for clinical diagnostics.
